Home The Word Brain | My Amedeo FAQ Privacy About | ||||||||||
The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al. |
Prostate Cancer |
Free Subscription
1 Anticancer Res |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Prostate Cancer is free of charge.
Salvage Radiotherapy PSMA PET/CT-guided in Men With PSA Recurrence.
Anticancer Res. 2024;44:2205-2210.
PubMed
Abstract available
Role of antihypertensive medicines in prostate cancer: a systematic review.
BMC Cancer. 2024;24:542.
PubMed
Abstract available
Patient-derived castration-resistant prostate cancer model revealed CTBP2
upregulation mediated by OCT1 and androgen receptor.
BMC Cancer. 2024;24:554.
PubMed
Abstract available
HIST3H2A promotes the progression of prostate cancer through inhibiting cell
necroptosis.
BMC Cancer. 2024;24:544.
PubMed
Abstract available
Correction to: High-grade prostate cancer demonstrates preferential growth in the
cranio-caudal axis and provides discrimination of disease grade in an MRI
parametric model.
Br J Radiol. 2024 Apr 30:tqae083. doi: 10.1093.
PubMed
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a
Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate
Cancer.
Clin Cancer Res. 2024 Apr 29. doi: 10.1158/1078-0432.CCR-23-3740.
PubMed
Abstract available
Refining clinical decision strategies and prostate cancer detection through fine
adjustments in the combination of PSA-derived parameters and MRI.
Eur Radiol. 2024 Apr 29. doi: 10.1007/s00330-024-10734.
PubMed
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update:
Treatment of Relapsing and Metastatic Prostate Cancer.
Eur Urol. 2024 Apr 29:S0302-2838(24)02306-6. doi: 10.1016/j.eururo.2024.
PubMed
Abstract available
OLIGOPELVIS and the "All You Can Eat" Strategy for Oligorecurrent Nodal Prostate
Cancer: Are We Already Full?
Eur Urol. 2024 Apr 27:S0302-2838(24)02307-8. doi: 10.1016/j.eururo.2024.
PubMed
Reply to Peter Ka-Fung Chiu, Xiaobo Wu, Giorgio Gandaglia, European Association
of Urology Young Academic Urologists Prostate Cancer Working Party. Beyond
Statistical Significance: Unveiling the Advantages of Transperineal Versus
Transrectal Prostate
Eur Urol. 2024 Apr 26:S0302-2838(24)02314-5. doi: 10.1016/j.eururo.2024.
PubMed
Metastatic Hormone-sensitive Prostate Cancer: Patient Selection for Prostate
Radiotherapy.
Eur Urol. 2024 Apr 26:S0302-2838(24)02308-X. doi: 10.1016/j.eururo.2024.
PubMed
Elective Pelvic Lymph Node Radiation Therapy and the Risk of Death in Patients
With Unfavorable-Risk Prostate Cancer: A Postrandomization Analysis.
J Clin Oncol. 2024 May 1:JCO2302394. doi: 10.1200/JCO.23.02394.
PubMed
Abstract available
Added Value of [18F]PSMA-1007 PET/CT and PET/MRI in Patients With Biochemically
Recurrent Prostate Cancer: Impact on Detection Rates and Clinical Management.
J Magn Reson Imaging. 2024 Apr 28. doi: 10.1002/jmri.29386.
PubMed
Abstract available
Real-World Experience with (177)Lu-PSMA-617 Radioligand Therapy After Food and
Drug Administration Approval.
J Nucl Med. 2024;65:735-739.
PubMed
Abstract available
PSMA PET/CT Dual-Time-Point Imaging: Nice to Have or Need to Have?
J Nucl Med. 2024 Jan 4:jnumed.123.266722. doi: 10.2967/jnumed.123.266722.
PubMed
Clinically Significant Prostate Cancer Detection Following Transrectal and
Transperineal Biopsy: Results of the Prostate Biopsy Efficacy and Complications
Randomized Clinical Trial.
J Urol. 2024 May 3:101097JU0000000000003979. doi: 10.1097/JU.0000000000003979.
PubMed
Abstract available
Outcomes Following Localized Prostate Cancer Treatment.
JAMA. 2024 Apr 29. doi: 10.1001/jama.2024.5489.
PubMed
Outcomes Following Localized Prostate Cancer Treatment.
JAMA. 2024 Apr 29. doi: 10.1001/jama.2024.5486.
PubMed
Outcomes Following Localized Prostate Cancer Treatment-Reply.
JAMA. 2024 Apr 29. doi: 10.1001/jama.2024.5492.
PubMed
Prostate Cancer Cases Might Rise to 3 Million Globally by 2040.
JAMA. 2024 May 3. doi: 10.1001/jama.2024.6729.
PubMed
Self-supervised multicontrast super-resolution for diffusion-weighted prostate
MRI.
Magn Reson Med. 2024;92:319-331.
PubMed
Abstract available
From biology to the clinic - exploring liver metastasis in prostate cancer.
Nat Rev Urol. 2024 Apr 26. doi: 10.1038/s41585-024-00875.
PubMed
Abstract available
Quantifying Y chromosome loss in primary and metastatic prostate cancer by
chromosome painting.
PLoS One. 2024;19:e0301989.
PubMed
Abstract available
Disrupting prostate cancer research: Challenge accepted; report from the 2023
Coffey-Holden Prostate Cancer Academy Meeting.
Prostate. 2024 Apr 29. doi: 10.1002/pros.24721.
PubMed
Abstract available
Differences in real-world outcomes by risk classification for localized prostate
cancer patients after radiation therapy.
Prostate. 2024 Apr 29. doi: 10.1002/pros.24720.
PubMed
Abstract available
Nutritional supplement with fermented soy in men with an elevated risk of
prostate cancer and negative prostate biopsies: General and oncological results
from the prospective PRAECAP trial.
Urology. 2024 Apr 24:S0090-4295(24)00300-5. doi: 10.1016/j.urology.2024.
PubMed
Abstract available
Incidence and Management of Radiation Cystitis After Pelvic Radiotherapy for
Prostate Cancer: Analysis from a National Database.
Urology. 2024 Apr 29:S0090-4295(24)00308-X. doi: 10.1016/j.urology.2024.
PubMed
Abstract available
Thank you for your interest in scientific medicine.